J. AntonioGLopezMDFACC,FAHA,FACP,FNLA, FASH, FASPC

Cardiology • Newbury Park, CA

Echocardiography, Preventive Cardiology, Exercise Physiology and Cardiac Rehabilitation, Cardiac Critical Care

Clinical Research Medical Director Cardiovascular and Metabolic Therapeutic Area Global Development Amgen

Join to view full profile

Dr. Lopez is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lopez's full profile

Already have an account?

Office
One Amgen Center Drive
27-3-A
Newbury Park, CA 91320
Phone+1 805-447-4596

Fax+1 805-855-4198

Summary

J. Antonio G. López, MD, FACC, FAHA, FACP, FCCP, FASE, FNLA, FASH, FASPC is Clinical Research Medical Director, Cardiovascular and Metabolic Therapeutic Area, Global Development at Amgen. He was most recently Cardiovascular Medical Director US Medical Organization and US Medical Organization CV Medical Advocacy Relations Lead at Amgen. He is a cardiologist, lipidologist, and hypertension specialist. Prior to joining Amgen in 2014, he was with Saint Alphonsus Medical Group Heart Care in Boise, Idaho. Dr. López was Director of Preventive Cardiology and CV Rehabilitation, Director of the Lipid Clinic, and Director of the LDL Apheresis Program at Saint Alphonsus Regional Medical Center in Boise, Idaho. He also served as Chair of Cardiology at Saint Alphonsus. In addition, he was Chair of CV Research and Education, Director of the Hypertension Consultation Service, and Director of the Carotid Intima-Media Thickness (CIMT) Program at Saint Alphonsus Medical Group Heart Care. His previous experience includes serving as Director of the Lipid Clinic and Director of CV Outpatient and Outreach Programs at the University of Iowa and Director of Cardiac Care and the Coronary Care Unit at the VA Medical Center in Iowa City, Iowa. He was also the Medical Director of Preventive Cardiology, CV Rehabilitation, the Lipid Clinic, and Prevention Center at the Prairie Heart Institute in Springfield, Illinois.
Dr. López received his medical degree Cum Laude from Harvard Medical School. He received the Henry J. Kaiser Family Foundation Merit Scholar Award at Harvard. He completed his residency in internal medicine at Cedars-Sinai Medical Center at the University of California, Los Angeles. He was a Research Fellow in the cardiac unit at the Massachusetts General Hospital. He completed a fellowship in cardiovascular diseases and interventional cardiology in the Department of Internal Medicine at the University of Iowa Hospitals and Clinics in Iowa City.

Education & Training

U Iowa Hosps and Clinics1986 - 1989
Cedars-Sinai Medical CenterResidency, Internal Medicine, 1983 - 1986
Harvard Medical SchoolClass of 1983
Massachusetts General HospitalFellowship, Cardiac Unit, 1980 - 1981
University of California at San DiegoB.A, General Biology, Cum Laude, 1973 - 1978

Certifications & Licensure

CA State Medical License 1985 - 2025
ID State Medical License 2007 - 2015
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Cardiovascular Disease

Awards, Honors, & Recognition

Cardiovascular Medicine Distinguished Alumnus Award Division of Cardiovascular Medicine, The University of Iowa, 2018
Physician of the Year, Hispanic Health Leadership Award National Hispanic Medical Association (NHMA), 2018
Distinguished Alumnus Award for Achievement University of Iowa Roy J. and Lucille A. Carver College of Medicine, 2018
Spirit of the US Award-Courage Amgen, 2016
Compassion Doctor Award MDx Medical, Inc,, 2010-2014
Vitals Patients’ Choice Award MDx Medical, Inc, 2008-2014
Distinguished Alumni Award Montgomery High School, 2013
Physician's Recognition Award, American Medical Association 1986, 1991. 1995, 1998, 2000, 2004
Chicano Alumni Association Recognition Award for Exceptional Contributions to the Field of Medicine University of California at San Diego (UCSD), 2001
Lifetime Achievement Award International Biographical Centre, 2001
America's Registry of Outstanding Professionals, Lifetime Member 2001
Hall of Fame, International Directory of Distinguished Leadership, American Biographical Institute 1999
Marquis Who’s Who in Medical Specialists 1998
Strathmore’s Who’s Who in Health Care 1998
International Who’s Who of Professionals 1998
Who’s Who National Registry, Lifetime Member 1998
Visiting Professor Department of Family Practice, Iowa Lutheran Hospital, Des Moines, IA, 1994
Quien Es Quien in U.S. Medical Care Quien Es Quien Publications, Forest Hills, NY, 1994
Visiting Cardiologist, Echocardiography Laboratory Hannover Medical School, Hannover, Germany, 1993
Outstanding Alumnus Montgomery High School, San Diego, CA, 1993
Veterans Administration, Merit Review Award 1990
Finalist (second prize), Young Investigators Award American College of Cardiology, 1989
Finalist, Alfred Soffer Research Award American College of Chest Physicians, 1988
National Trainee Award American Federation for Clinical Research, 1988
Midwest-Trainee Award American Federation for Clinical Research and The Central Society for Clinical Research, 1987
American College of Cardiology/Syntex Continuing Medical Education Scholarship Award 1987
American Heart Association, Iowa Affiliate Fellowship Award 1986
Iowa Cardiovascular Center Institutional Research Fellowship Award University of Iowa College of Medicine, 1986
Henry J. Kaiser Family Foundation Merit Scholar National Medical Fellowships, Inc, 1983
M.D. “Cum Laude” Harvard Medical School, 1983
Soma Weiss Undergraduate Assembly Harvard Medical School, 1983
Harvard Medical School Research Fellowship 1981
Varsity Letterman, Intercollegiate Tennis University of California at San Diego, 1974
Volunteer Award of Recognition Veterans Administration Hospital, La Jolla, California, 1973
San Ysidro Womens Club Scholarship 1973
California Scholarship Federation, Life Member, Chapter 9095 1973
Fellow (FACC) American College of Cardiology
Patients’ Choice Award MDx Medical, Inc.2008-2011
Veterans Administration, Associate Investigator Award 1987-1990
Dean’s and Provost’s Honor List University of California at San Diego, 1973-1978
Mexican American Educators Scholar, San Diego County, Mexican American Educators Association 1973-1978
California State Scholarship 1973-1978
Join now to see all

Publications & Presentations

PubMed

2 citations
Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies.
Frederick J Raal, Robert A Hegele, Andrea Ruzza, J Antonio G López, Ajay K Bhatia
Arteriosclerosis, Thrombosis, and Vascular Biology. 2024-05-01
17 citations
Lipoprotein(a) and Major Adverse Cardiovascular Events in Patients With or Without Baseline Atherosclerotic Cardiovascular Disease.
Adam N Berman, David W Biery, Stephanie A Besser, Avinainder Singh, Arthur Shiyovich
Journal of the American College of Cardiology. 2024-03-05
1 citations
Long-Term Efficacy of Evolocumab in Patients With or Without Multivessel Coronary Disease.
Daniel J McClintick, Michelle L O'Donoghue, Gaetano M De Ferrari, Jorge Ferreira, Xinhui Ran
Journal of the American College of Cardiology. 2024-02-13

Journal Articles

Quantification of LDL-Cholesterol corrected for molar concentration of Lp(a)
Rosenson, R.S., López, J.A.G., Monsalvo, M.L., Wu, Y., Wang, H., Marcovina, S.M., Cardiovasc Drugs Ther. 2022 https://doi.org/10.1007/s10557-022-07407-y., 2022
Reduction of Lipoprotein(a) in Persons with Cardiovascular Disease
O'Donoghue, M.L., Rosenson, R.S., Gencer, B., López, J.A.G., Lepor, N.E., Baum, S. J., Stout, E., Gaudet, D., Knusel, B., Kuder, J.F., Ran, X., Murphy, S.A., Wang, H.,..., N Engl J Med. 2022; 387:1855-1864., 2022
Long-Term Safety, Lipids, and Major Adverse Cardiovascular Events with Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease: Primary Results ...
O’Donoghue, ML., Giugliano, RP., Wiviott, SD., Atar, D., Keech, K., Kuder, J., Im, K., Murphy, S., Flores-Arredondo, JH., López, JAG., Elliott-Davey, M., Wang, B., Mon..., Circulation. 2022;146:1109-1119., 2022
Study Design and Rationale for the OCEAN(a)-DOSE (Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction-DOSE Finding Study) Trial
O'Donoghue, M.L, López, J.A.G., Knusel, B., Gencer, B., Wang, H., Wu, Y., Kassahun, H. and Sabatine M.S., Am. Heart J. 2022;251:61-69., 2022
Lipoprotein(a) and the Risk for Coronary Heart Disease and Ischemic Stroke Events Among Black and White adults with Cardiovascular Disease
Colantonio, L.D., Bittner, V., Safford, M.M., Marcovina, S., Brown, T.D., Jackson, E.A., López, J.A.G., Monda, K.L., Plante, T.B., Kent, S., Muntner, P., and Rosenson,..., J Am Heart Assoc. 2022;11:e025397., 2022
Long-term effects of evolocumab in patients with HIV and dyslipidemia: Results from the open-label extension period of the BEIJERINCK study
Boccara, F., Caramelli, B., Calmy, A., Kumar, P., López, J.A.G., Bray, S., Cyrille, M., and Rosenson, R.S., AIDS. 2022;36:675-682., 2022
Diabetes Associated Residual Atherosclerotic Cardiovascular Risk in Statin-Treated Patients with Prior Atherosclerotic Cardiovascular Disease
Zhao, Y., Xiang, P., Coll, B., López, J.A.G., and Wong, N.D., J Diabetes Complications. 2021;35:107767., 2021
Effects of Evolocumab on Low-Density Lipoprotein Cholesterol, Non–High Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a) by Race and Ethnicity: A M...
Daviglus, M.L., Ferdinand, K.C., López, J.A.G., Wu, Y., Monsalvo, M.L., and Rodriguez, C.J., J Am Heart Assoc. 2021;10:e016839., 2021
Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: an analysis from BANTING and BERSON
Lorenzatti, A.J., Monsalvo, M.L, López, J.A.G., Wang, H., and Rosenson, R.S., Cardiovasc Diabetol. 2021; 20:94., 2021
Five-Year Residual Atherosclerotic Cardiovascular Disease Risk Prediction Model for Statin Treated Patients with Known Cardiovascular Disease
Wong, N.D., Zhao, Y., Xiang, P., Coll, B., and López, J.A.G., Am J Cardiol. 2020;137:7−11., 2020
A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations.
Koren, M.J., Jones, P.H., Robinson, J.G., Sullivan, D., Cho, L., MD, Hucko, T., Lopez, J.A.G., Fleishman, A.N., Somaratne, R., and Stroes, E., Cardiol Ther. 2020;9(2):447-465., 2020
Evolocumab Effects on Lipoproteins, Measured by High-Performance Liquid Chromatography.
Masuda, D., Kiyosue, A., Hirayama, A., Shimauchi, J., Lopez, J.A.G., Miyawaki, K and Yamashita, S., J Atheroscler Thromb. 2020;27:1183-1207., 2020
Evolocumab Use in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-blind BEIJERINCK Study.
Boccara, F., Kumar, P.N., Caramelli, B., Calmy, A., López, J.A.G., Bray, B., Cyrille, M., and Rosenson, R.S., J Am Coll Cardiol. 2020;75:2570-2584., 2020
Effect of Evolocumab on Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies.
Toth, P.P., Jones, S.R., Monsalvo, M.L., Elliott-Davey, M., López, J.A.G., and Banach, M., J Am Heart Assoc. 2020;9: e014129., 2020
Long-Term Evolocumab in Patients with Familial Hypercholesterolemia
Santos, R.D., Stein, E.A., Hovingh, G.K., Blom, D.J., Soran, H., Watts, G.F., Lopez, J.A.G., Bray, S., Kurtz, C.E., Hamer, A.W., and Raal, F.J., J Am Coll Cardiol. 2020;75: 565-574., 2020
Evolocumab treatment in patients with HIV and hyperlipidemia/mixed dyslipidemia: BEIJERINCK study design and baseline characteristics
Boccara, F., Kumar, P., Caramelli, B., Calmy, A., López, J.A.G., Bray, S., Cyrille, M., and Rosenson, R.S., Am Heart J. 2020;220;203-212., 2020
Prevalence and Treatment of Familial Hypercholesterolemia Among Young Adults with Myocardial Infarction: the Partners YOUNG-MI Registry
Singh, A., Gupta, A., Collins, B.L., Qamar, A., Monda, K.L., Biery, D., Lopez, J.A.G., de Ferranti, S.D., Plutzky, J., Cannon, C.P., Januzzi, J.L., Marcelo F., Di Ca..., J Am Coll Cardiol. 2019;73: 2439–50., 2019
Cardiovascular Events and Death after Myocardial Infarction or Ischemic Stroke in Older Medicare Population
Li, S., Wang, X., Quan, Y, Xiang P, Wade, SW., Guo, H., Lopez, J.A.G., Herzog, CA and Handelsman, Y., Clin. Cardiol. 2019;42:391–399, 2019
Effects of Evolocumab on the ApoA1 Remnant Ratio: A Pooled Analysis of Phase 3 Studies
May, H., Muhlestein, J.B., Ma, Y., López, J.A.G., Crespo, B.C., and Nelson, J., Cardiol Ther. 2019;8:91-102., 2019
The STatin Adverse Treatment Experience (STATE) Survey: Experience of Patients Reporting Side Effects of Statin Therapy
Cheeley, M.K., Jacobson, T., Jones, P., LaForge, R., Maki, K., Cheeley, M.K., López, J.A.G., Xiang, P., Bushnell, D., Martin, M., and Cohen, J.D., J Clin Lipidol. 2019;13:415-424., 2019
PCSK9 loss-of-function variants and lipoprotein(a) phenotypes among black US adults.
Mefford, M.T., Marcovina, SM., Bittner, V., Cushman, M., Brown, TM., Farkouh, M.E., Tsimikas, S., Monda, K.L., López, J.A.G., Marcovina, SM., Muntner, P., and Rosenson..., J Lipid Res. 2019;60:1946–1952., 2019
Early Challenges for Patient Access to PCSK9 Inhibitors: Payor Rejections and Copay-Induced Abandonment.
Navar, A.M., Taylor B., Mulder, H., Fievitz, E., Monda, K., Fievitz, A., Maya, J., Lopez, J.A., and Peterson, E.D., JAMA Cardiol. 2017;2(11);1217-1225, 2017
Residual atherosclerotic cardiovascular disease risk in statin-treated adults: The Multi-Ethnic Study of Atherosclerosis
Wong, N D., Zhao Y., Quek, R.G.W., Blumenthal, R.S., Budoff, M.J., Cushman, M., Garg, P., Sandfort, V. Tsai, M., and Lopez J.A.G, J Clin Lipidol. 2017;11:1223-1233, 2017
Vascular Responses to Endothelin in Atherosclerotic Primates.
Lopez, J.A.G., Armstrong, M.L., Piegors, D.J., and Heistad, D.D, Arteriosclerosis
Erratum. Effect of Early and Advanced Atherosclerosis on Vascular Responses to Serotonin, Thromboxane A2, and ADP.
Lopez, J.A.G., Armstrong, M.L., Piegors, D.J., and Heistad, D.D, Circulation
Join now to see all

Books/Book Chapters

Da La Mano A Tu Hermano.
Chapter: We Need Chicano Health Professionals
Page 1 - 2Lopez, J.A.: El ProblemaNational Chicano Health Organization, Harvard Medical School, Boston
Pathobiology of the Human Atherosclerotic Plaque.
Chapter: Hemodynamic Consequences of Changes in the Artery Wall During Atherogenesis
Page 481 - 496Lopez, J.A., Harrison, D.G., Armstrong, M.L., and Heistad, D.DEditors: S. Glagov, W.P. Newmann III, and S.A. Schaffer.Springer-Verlag New York, New York
Cardiovascular Clinics:Preventive Aspects of Coronary Heart Disease.
Chapter: Reversibility of Atherosclerosis
Page 113 - 126Armstrong, M.L., Heistad, D.D., Megan, M.D., Lopez, J.A.G., and Harrison, D.GEditors: E.D. Frohlich.F.A. Davis Company, Philadelphia
Proceedings Volume of the International Symposium on “Serotonin:From Cell Biology to Pharmacology and Therapeutics.
Chapter: Responses to Serotonin in Atherosclerotic and Hypertensive Blood Vessels
Page 137 - 140Heistad, D.D., Lopez, J.A.G., and Mayhan, W.GEditors: R. Paoletti, P.M. Vanhoutte, N. Vbrunello, and F.M. Maggi.Kluwer Academic Publishers
Endothelium-Derived Contracting Factors.
Chapter: Atherosclerosis Alters Vascular Responses to Activated Platelets and Leukocytes
Page 155 - 161Heistad, D.D., Lopez, J.A.G., and Armstrong, M.LEditors: G.M. Rubanyi and P.M. Vanhouette.S. Karger Publications, Basel, Switzerland
Advances in Experimental Medicine and Biology:Tobacco Smoking and Atherosclerosis.
Chapter: Atherosclerosis Alters the Response to Activated Platelets and Leukocytes
Page 173 - 180Heistad, D.D., Lopez, J.A., and Armstrong, M.LEditors: J.N. Diana.Plenum Publishing Corporation, New York
Drugs Affecting Lipid Metabolism (Int. Congr. Ser Exerpta Med).
Chapter: Old World Monkeys and Atherosclerosis Research
Page 485 - 488Armstrong, M.L., Heistad, D.D., Harrison, D.G., and Lopez, J.A.GEditors: A.M. Gotto and L.C. Smith.Elsevier Science Publishers
Coronary Circulation in Physiological and Pathological States.
Chapter: Effects of Atherosclerosis and Regression of Lesions
Page 103 - 116Heistad, D.D., Lopez, J.A., Faraci, F.M., and Armstrong, M.LEditors: M. Nakamura and P.M. Vanhouette.Springer-Verlag Tokyo, Tokyo, Japan
Progress and Promise for an Effective Quantitative Evaluation of Atherosclerosis in Animals and Man.
Chapter: Constriction and Dilatation in Atherosclerotic and Hypertensive Arteries
Page 251 - 260Heistad, D.D., Lopez, J.A.G., Faraci, F.M., and Armstrong, M.LEditors: R.W. Wissler, M.G. Bond, M. Mercuri and P. Tanganelli.Plenum Publishing Corporation, New York
Transactions of the Association of American Physicians.
Chapter: Vascular Response to Activation of Leukocytes in Atherosclerotic Primates
Page 150 - 154Heistad, D.D., Lopez, J.A.G., Mugge, A., Densen, P., Padgett, R., and Armstrong, M.LWaverly Press, Baltimore
Cardiovascular Therapeutics.
Chapter: Treatment of Hypertension in the Patient with Cardiovascular Disease
Page 503 - 514Haynes, W.G., Lopez, J.A.G., and Mark A.LEditors: T.W. Smith.W.B. Saunders Company, Philadelphia, PA
Primary care Management of Heart Disease.
Chapter: Effects of Renal Disease on the Heart, Chapter 7, Section 44
Page 477 - 480Katholi, R.E., Lopez, J.A.G., and Bilinsky, R.TEditors: G.A. Taylor.Mosby, Inc, St. Louis, MO
Join now to see all

Abstracts/Posters

Activation of Leukocytes Constricts Large Cerebral Arteries in Atherosclerotic Monkeys.
Heistad, D.D., Faraci, F.M., Lopez, J.A.G., and Armstrong, M.L, J. Cereb. Blood Flow Metab
Coronary Sinus Endothelin Levels Rise After Coronary Balloon Angioplasty.
Kadel, K.A., Lopez, J.A.G., Rossen, J.D., Winniford, M.D., Talman, C.L., and Revtyak, G.R, Circulation
Effect of Intravascular Complement C5a in Atherosclerotic Primates.
Lopez, J.A.G., Mugge, A., Densen, P., Piegors, D.J., and Heistad, D.D, Circulation
Cigarette Smoking Produces Constriction of Large Coronary Arteries in Humans.
Quillen, J.E., Lopez, J.A.G., Rossen, J.D., Talman, C.L., and Winniford, M.D, J. Am. Coll. Cardiol
Human Leukocytes Modulate Tone in Normal and Atherosclerotic Arteries in Vitro: Implications for Vasospasm.
Mugge, A., Lopez, J.A.G., Densen, P., Waak, B.J., and Heistad, D.D, J. Am. Coll. Cardiol
Vascular Responses to Activation of Leukocytes in Vivo After Regression of Atherosclerosis.
Lopez, J.A.G., Mugge, A., Armstrong, M.L., Piegors, D.J., and Heistad, D.D, J. Am. Coll. Cardiol
Vascular Response to Human Platelets: Intraluminal vs. Albuminal Activation.
Kaul, S., Waak, B.J., Mugge, A., Padgett, R.C., Lopez, J.A.G., and Heistad, D.D, FASEB J
Localization of the Increase in Coronary Vascular Resistance After Cigarette Smoking in Humans.
Quillen, J.E., Rossen, J.D., Lopez, J.A.G., DeBoel, S.L., and Winniford, M.D, Circulation
Vascular Effects of Leukocytes.
Heistad, D.D., Lopez, J.A.G., Armstrong, M.L., and Mugge, A, J. Cell. Biochem
Coronary Dilation with Intravenous Dipyridamole and Adenosine. A Comparative Study.
Rossen, J.D., Stenberg, R.G., Lopez, J.A.G., Talman, C.L., and Winniford, M.D, Circulation
Vascular Responses to Activation of Leukocytes in Atherosclerotic Primates.
Heistad, D.D., Lopez, J.A.G., Mugge, A., Densen, P., Padgett, R., and Armstrong, M.L, Clin., Res
Altered Vascular Responses to Activated Platelets from Hypercholesterolemic Humans.
Kaul, S., Waak, B.J., Mugge, A., Brooks, R.M., Lopez, J.A.G., and Heistad, D.D, Clin. Res
Vascular Effects of Leukocytes.
Heistad, D.D., Lopez, J.A.G., Armstrong, M.L., and Mugge, A, J. Cell. Biochem
Aktivierte Leukozyten Kontraheiren Arteriosklerotische Arterien in Vivo Durch Die Freiserzung von Thromboxane A2.
Mugge, A., Heistad, D.D., and Lopez, J.A.G, Z. Kardiol
Vasoconstriction Induced by Activated Leukocytes: Implications for Vasospasm.
Mugge, A., Lopez, J.A.G., and Heistad, D.D, Eur. Heart J
Are Intracoronary Doppler Flow Velocity Measurements Accurate for Assessment of Coronary Flow Reserve?
Shammas, N.W., Thondapu, V., Lopez, J.A.G., Winniford, M.D. and Rossen, J.D, J. Am. Coll. Cardiol
Effect of Pretreatment with Nitroglycerin on Coronary Flow Reserve Measured Using Bolus Intracoronary Adenosine.
Shammas, N.W., Thondapu, V., Gerasimou, E.M., Lopez, J.A.G., Winniford, M.D., and Rossen, J.D, Circulation
Detection of Early Necrosis in Low Flow Myocardial Ischemia Using Antimyosin.
Timmis, A.D., Lopez, J.A., J.T., Khaw, B.A., Haber, E., and Powell, W.J, Circulation
Complement C5a Produces Vasoconstriction in Atherosclerotic But Not Normal Primates in Vivo.
Lopez, J.A.G., Mugge, A., Densen, P., Piegors, D.J., Armstrong, M.L., and Heistad, D.D, Clin. Res
Activated Human Leukocytes Produce Endothelium-Independent Vasoconstriction in Normal and Atherosclerotic Primates in Vitro.
Mugge, A., Lopez, J.A.G., Densen, P., Waack, B., and Heistad, D.D, Clin. Res
Vasoconstriction in Response to Activation of Leukocytes Persists After Regression of Atherosclerosis.
Lopez, J.A.G., Mugge, A., Armstrong, M.L., Piegors, D.J., and Heistad, D.D, Clin. Res
Response of Cerebral and Ocular Vessels to Activated Leukocytes in Atherosclerotic Primates.
Lopez, J.A.G., Faraci, F.M., Breese, K.R., Armstrong, M.L., and Heistad, D.D, Clin. Res
Augmented Arterial Constriction to Serotonin in Atherosclerotic Primates: An Angiographic Study.
Rossen, J.D., Piegors, D.J., and Lopez, J.A.G, FASEB J
Effect of Intravascular Collagen in Atherosclerotic Primates.
Lopez, J.A.G., Hoak, J.C., Armstrong, M.L., Piegors, D.J., and Heistad, D.D, J. Am. Coll. Cardiol
Vascular Responses to Endothelin in Atherosclerotic Primates.
Lopez, J.A.G., Armstrong, M.L., Piegors, D.J., and Heistad, D.D, Circulation
Join now to see all

Lectures

Neurogenic Vasoactive Properties of Ouabain.
Multiple locations, 1982, 1983
Nonbacterial Thrombotic Endocarditis: An Echocardiographic-pathologic Correlation.
American College of Physicians, Associates Program, Southern California Regions I, II, III and Hawai
Responsiveness of Iliac Collateral Vessels to Vasoconstrictor Stimuli in Atherosclerotic Primates.
Multiple locations
Vascular Responses to Platelet Produces in Primates with Early and Advanced Atherosclerosis.
Multiple locations
Mechanisms of Vasospasm in Atherosclerosis.
Cardiovascular Physiology Seminar, New England Medical Center, Tufts University School of Medicine
Role of Platelets and Leukocytes in Vasospasm.
Featured Research Symposium, Endothelial Cell Function I, AAP/ASCI/AFCR National Meeting, Washington
Vascular Responses to Activated Platelets in Atherosclerotic Primates.
Peripheral Circulation I Session, 72nd Annual Meeting, FASEB, National Meeting, Las Vegas, Nevada
Alteration of Vascular Responses to Platelets and Leukocytes in Atherosclerosis.
Cell Biology Session, 21st Hugh Lofland Conference on Arterial Wall Metabolism, Chicago, Illinois
Mechanisms of Vasospasm.
Video Magazine, 54th Annual Scientific Assembly, American College of Chest Physicians, Anaheim
Mechanisms of Vasospasm in Primates with Early Atherosclerosis.
Pathogenesis and Diagnosis of Coronary Artery Disease Session, 54th Annual Scientific Assembly
Vascular Responses to Leukocyte Products in Atherosclerotic Primates.
Young Investigators’ Awards Competition,38th Annual Scientific Session,American College of Cardiolgy
Vascular Responses to Endothelin in Atherosclerotic Primates.
Multiple locations
Effect of Intravascular Collagen in Atherosclerotic Primates.
Endothelium and Vasomotion Session, 39th Annual Scientific Session, American College of Cardiology
Response of Cerebral and Ocular Vessels to Activated Leukocytes in Atherosclerotic Primates.
Cardiovascular I: Coronary Atherosclerosis/Lipid Session, AAP/ASCI/AFCR National Meeting, Washington
Mechanisms of Vasospasm in Atherosclerosis.
Cardiovascular Conference, Sharp Memorial Hospital, San Diego, California
Vasoconstriction in Response to Activation of Leukocytes Persists After Regression of Atherosclerosis.
Cardiovascular II: Coronary Disease and Endothelium Session, 48th Annual Meeting Midwest Section
Vascular Response to Activation of Leukocytes in Vivo After Regression of Atherosclerosis.
Coronary Artery Disease: Basic Aspects Session, 40th Annual Scientific Session, Atlanta, Georgia
ACLS in Perspective: Myocardial Infarction.
ACLS Provider/Recertification Course, Fallbrook Hospital District, Fallbrook, California
Coronary Vasospasm.
Nursing Rounds, Fallbrook Hospital District, Fallbrook, California
Hypertension 1991.
Grand Rounds, Fallbrook Hospital District, Fallbrook, California
Preventive Cardiology.
Temecula Talks Television Program, Temecula, California
ypercholesterolemia.
Care of the Cardiac Patient, Inland Valley Regional Medical Center, Wildomar, California
Latinos and Chronic Disease Update: Diabetes, Hypertension and Cholesterol.
4th Annual Conference, The Chicano/Latino Medical Association of California, Los Angeles, California
Clinical Perspectives on Blood Lipids.
Medical Education Program, Temecula, California
Hypercholesterolemia.
Fallbrook Village Rotary, Fallbrook, California
Join now to see all